|
May 28
|
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners
|
|
May 27
|
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
|
|
May 27
|
Pfizer headquarters conversion project in Manhattan gets $720m loan
|
|
May 26
|
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
|
|
May 24
|
Junkiest Junk Is Offering a Warning Sign for Debt
|
|
May 24
|
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost
|
|
May 24
|
Down 63%, Should You Buy the Dip on Pfizer?
|
|
May 24
|
Charting the Global Economy: Long-Term Bond Yields Soar Around the World
|
|
May 24
|
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
|
|
May 24
|
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
|
|
May 23
|
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
|
|
May 23
|
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success
|
|
May 23
|
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
|
|
May 23
|
Astellas and Pfizer’s Xtandi combo reduces death risk in prostate cancer trial
|
|
May 22
|
Was Jim Cramer Right About Pfizer Inc. (PFE)?
|
|
May 22
|
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
|
|
May 22
|
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
|
|
May 22
|
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
|
|
Apr 28
|
Eli Lilly, Pfizer Risk Billions in Losses From Trump's 25% Pharma Tariffs
|
|
Apr 28
|
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
|